Compare Coupang Inc (CPNG) vs Novartis AG (NVS) Price & Performance

Coupang (CPNG) trades at $15.41, up 4.05% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with support at $15 and resistance at $16. Fundamentally, revenue grew to $34.53B in 2025 with positive net income of $208M, though profitability metrics remain challenged with negative ROE and high P/E ratio. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $25.25 consensus price target.

Coupang presents a growth opportunity with dominant South Korean market position and expanding logistics network, but faces execution risks from recent earnings disappointments and competitive pressures. The significant gap between current price and analyst targets suggests upside potential, though investors must weigh high valuation multiples against profitability challenges and geopolitical risks highlighted in recent US-Korea trade tensions.

NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.

The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.